Frequently Relapsing or Steroid-Dependent Minimal Change Disease: Management When Glucocorticoids Fail to Maintain Remission
Clinical Scenario
In a significant minority of patients with minimal change disease, the initial response to glucocorticoid therapy does not hold. These patients either relapse frequently after achieving remission or become dependent on continuous steroid use to prevent relapse — a pattern seen in up to 33% of cases.
Previous Treatment & Reason for Escalation
Oral glucocorticoids (prednisone) were used to retreat each relapse and achieve remission of nephrotic syndrome. This protocol applies when that approach fails to sustain durable remission — the patient continues to relapse frequently or cannot be successfully weaned off steroids.
Next-Step Approach (Partial Overview)
The next step involves adding a second-line agent chosen specifically to reduce or eliminate ongoing glucocorticoid exposure. Multiple distinct classes of agents — including immunosuppressants and B-cell-targeted therapies — are considered at this stage, each suited to different patient profiles. The complete agent selection, clinical considerations, and treatment sequencing are available in the full protocol below.
Treatment Goals
Maintenance of remission and reduction of relapse rate.
References
DOI: 10.1038/kisup.2012.18
- Most patients will relapse infrequently after remission, but a significant minority will relapse frequently or become steroid-dependent.
- Up to 33% of patients will become frequent relapsers (11%–29%) or steroid-dependent (14%–30%).
- We recommend cyclophosphamide, rituximab, CNIs, or mycophenolic acid analogs (MPAA) for the treatment of frequently relapsing/steroid-dependent MCD, rather than prednisone alone or no treatment (1C).
- Observational studies and small RCTs showed that all 4 categories of agents reduce relapse rate and induce remission in adult patients with FR/SD MCD.
View source ↗